Epoetin_alfa: profile and news

High-Dose Epoetin Alfa (Procrit) Every 3 Weeks Effective for ...  Dec 14, 2005
DG News ATLANTA, GA -- December 14, 2005 -- Epoetin alfa (Procrit) 80,000 units administered every three weeks to patients on an every three-week chemotherapy regimen ...

Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ...  Dec 11, 2005
Business Wire (press release), Amgen revolutionized anemia treatment with the development of recombinant erythropoietin, Epoetin alfa. Building on this heritage ...

Epogen: reports of pure red cell aplasia and severe anemia ...  Dec 11, 2005
Xagena.it, Amgen and FDA notified HealthCare Professionals of revision to sections of the prescribing information for Epogen ((Epoetin alfa ). ...

Higher doses of pegylated interferon or ribavirin improve ...  Dec 8, 2005
Aidsmap, ...of chronic Hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and Epoetin alfa (EPO) enhances ...

Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ...  Dec 7, 2005
Cancer Consultants (press release), Researchers from Italy have demonstrated that long-acting Aranesp (darbepoetin alfa) is as effective as Procrit® (epoetin alfa) for the treatment of patients ...

Zacks.com announces that Richard Moroney highlights the following ...  Dec 15, 2005
Business Wire (press release), They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ...

b>May 4, 2006
...friendly therapy option for anaemia, which is currently treated with injectable recombinant forms of EPO such as Amgen's Epogen (epoetin alfa) and Aranesp ... - Pharma Times (subscription),

Data From Correction of Hemoglobin and Outcomes in Renal ... Apr 20, 2006
The study was conducted to understand whether anemic patients with chronic kidney disease not on dialysis, treated with PROCRIT(R) (Epoetin alfa) to an ... - International News Service,

Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ... Apr 20, 2006
Sales of EPOGEN(R) (Epoetin alfa) increased 4 percent to $604 million in the first quarter of 2006 versus the first quarter of 2005, driven primarily by ... - Webbolt Business News,

Dose-Dense R-CHOP-14 Can Be Safely Administered to NHL Patients ... Apr 25, 2006
...studies have suggested that prophylactic administration of granulocyte-colony stimulating factor (Neupogen® or Neulasta) and epoetin alfa (Procrit® or Aranesp ... - Cancer Consultants (press release),

Source: Rockwell Medical Technologies, Inc. Apr 20, 2006
The study results also appeared to demonstrate a reduction in the amount of Epoetin-alfa (EPO) needed during the dialysis treatment. ... - Yahoo! News (press release)

Fibrogen, Astellas Anemia Deal: $300M, Plus $465M In Milestones Apr 28, 2006
...to mind, typically so does Amgen Inc., of Thousand Oaks, Calif., with its blockbuster Aranesp, the second generation of Epogen (epoetin alfa), which Johnson & ... - BioWorld Online (subscription),

Other information

Indication
For treatment of anemia (from renal transplants or certain HIV treatment)

Pharmacology
Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.

Mechanism Of Action
Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.

Drug Category
Antianemic Agents; hematopoietic agents (20:16.00)

Brand Names/Synonyms
Erythropoietin precursor;Epoetin; Epogen (Amgen Inc.); Epogin (Chugai); Epomax (Elanex); Eprex (Janssen-Cilag. Ortho Biologics LLC); NeoRecormon (Roche); Recormon (Roche); Procrit (Ortho Biotech)

Dosage Forms
SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human erythropoietin

Chemical Formula
C815H1317N233O241S5

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
BIOD00103

CAS Registry Number
11096-26-7